$26.91
1.51%
Downside
Day's Volatility :11.0%
Upside
9.64%
67.34%
Downside
52 Weeks Volatility :79.17%
Upside
36.23%
Period | Cassava Sciences Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 37.09% | 5.1% | 0.0% |
6 Months | 39.79% | 4.9% | 0.0% |
1 Year | 27.78% | 16.6% | 0.0% |
3 Years | -43.75% | 13.2% | -22.3% |
Market Capitalization | 1.4B |
Book Value | $3.94 |
Earnings Per Share (EPS) | -2.59 |
Wall Street Target Price | 103.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -37.43% |
Return On Equity TTM | -8.35% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -68.0M |
EBITDA | -130.6M |
Diluted Eps TTM | -2.59 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.77 |
EPS Estimate Next Year | -0.8 |
EPS Estimate Current Quarter | -0.4 |
EPS Estimate Next Quarter | -0.42 |
What analysts predicted
Upside of 282.76%
Sell
Neutral
Buy
Cassava Sciences Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Cassava Sciences Inc | -10.89% | 39.79% | 27.78% | -43.75% | 2105.74% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Cassava Sciences Inc | NA | NA | NA | -1.77 | -0.08 | -0.37 | NA | 3.94 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Cassava Sciences Inc | Buy | $1.4B | 2105.74% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Cassava Sciences Inc
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 9.3%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 113.0%
BlackRock Inc
Vanguard Group Inc
State Street Corporation
Geode Capital Management, LLC
Gallacher Capital Management LLC
Northern Trust Corp
refer to descriptions included in the company's filings with the securities and exchange commission for more information about the company. the company does not intend to update and does not take responsibility for any information published on linkedin.
Organization | Cassava Sciences Inc |
Employees | 29 |
CEO | Mr. Richard Jon Barry |
Industry | Pharmaceuticals: Other |
A Spac I Acquisition Corp
$26.91
-8.62%
Keyarch Acquisition Corp
$26.91
-8.62%
Connexa Sports Technologies Inc
$26.91
-8.62%
Us Value Etf
$26.91
-8.62%
First Wave Biopharma Inc
$26.91
-8.62%
Global X Msci Next Emerging
$26.91
-8.62%
Fat Projects Acquisition Corp
$26.91
-8.62%
Capital Link Global Fintech
$26.91
-8.62%
Applied Uv Inc
$26.91
-8.62%